{"title":"Gemini Curcumin Suppresses Gastric Cancer AGS Cell Proliferation Through Modulation of <i>lncRNA CCAT2</i> and <i>c-Myc</i> Genes.","authors":"Nasim Jabbari, Salar Hafez Ghoran, Haniyeh Semsari, Bashdar Mahmud Hussen, Esmaeil Babaei","doi":"10.4274/tjps.galenos.2021.03502","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Gemini surfactant nanocurcumin (Gemini-Cur) is a novel formulation of Curcumin (Cur) with dramatic suppressive effects on cancer cells. Here, we investigated the cancer effects of Gemini-Cur in a human gastric adenocarcinoma cell-line (AGS) through the evaluation of the expression of long non-coding RNAs colon cancer-associated transcript-2 (<i>CCAT2</i>) and its downstream <i>c-Myc</i> as known oncogenic modulators of tumorigenesis.</p><p><strong>Materials and methods: </strong>The AGS cells were treated with Gemini-Cur and pure Cur in a time- and dose-dependent manner. The toxicity of Gemini-Cur was studied using 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide and scratch tests. Furthermore, real-time polymerase chain reaction and Western blotting techniques were employed to evaluate the expression of genes.</p><p><strong>Results: </strong>Gemini-Cur significantly affected the viability of AGS cells in a dose- and time-dependent manner with inhibitory concentration 50 values of 59.32, 40.88, and 19.63 µM during 24, 48, and 72 h, respectively. Our findings showed that Gemini-Cur effectively decreased the expression levels of <i>lnc-CCAT2</i> and <i>c-Myc</i> genes. Western blotting analysis also confirmed the down-regulation of <i>c-Myc</i> in treated samples compared to controls.</p><p><strong>Conclusion: </strong>Gemini-Cur attenuates the proliferation of AGS cells partly through modulation of the <i>lncCCAT2</i>-related pathway.</p>","PeriodicalId":23378,"journal":{"name":"Turkish Journal of Pharmaceutical Sciences","volume":"19 3","pages":"239-245"},"PeriodicalIF":1.8000,"publicationDate":"2022-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9254092/pdf/TJPS-19-239.pdf","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Turkish Journal of Pharmaceutical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4274/tjps.galenos.2021.03502","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 3
Abstract
Objectives: Gemini surfactant nanocurcumin (Gemini-Cur) is a novel formulation of Curcumin (Cur) with dramatic suppressive effects on cancer cells. Here, we investigated the cancer effects of Gemini-Cur in a human gastric adenocarcinoma cell-line (AGS) through the evaluation of the expression of long non-coding RNAs colon cancer-associated transcript-2 (CCAT2) and its downstream c-Myc as known oncogenic modulators of tumorigenesis.
Materials and methods: The AGS cells were treated with Gemini-Cur and pure Cur in a time- and dose-dependent manner. The toxicity of Gemini-Cur was studied using 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide and scratch tests. Furthermore, real-time polymerase chain reaction and Western blotting techniques were employed to evaluate the expression of genes.
Results: Gemini-Cur significantly affected the viability of AGS cells in a dose- and time-dependent manner with inhibitory concentration 50 values of 59.32, 40.88, and 19.63 µM during 24, 48, and 72 h, respectively. Our findings showed that Gemini-Cur effectively decreased the expression levels of lnc-CCAT2 and c-Myc genes. Western blotting analysis also confirmed the down-regulation of c-Myc in treated samples compared to controls.
Conclusion: Gemini-Cur attenuates the proliferation of AGS cells partly through modulation of the lncCCAT2-related pathway.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
